A clinical trial is being conducted at the University of Florida to
determine whether the orphan drug NTBC (Orfadin) may reduce or prevent
undesirable side effects of the investigational drug, dichloroacetate
(DCA) in patients with congenital lactic acidosis. Patients who participate
in this trial will be admitted six times to the General Clinical Research
Center at the University of Florida. The first visit will require five
days of baseline tests and dietary education, while the remaining
admissions will be for two or three days. A parent will stay in the same
room as his or her child throughout each visit. Travel assistance is
available through Mercy Medical Airlift.
For additional information, contact Margaret Francis, ARNP, the study
coordinator, at (352) 392-2321, fax: (352) 846-0990, or e-mail:
francma@medicine.ufl.edu or Peter W. Stacpoole, PhD, MD, at
stacpool@gcrc.ufl.edu.
Read about events on Capitol Hill, funding for rare-disease research, and other topics of interest from NORD's office in Washington, DC.
